Rulan Griesel is currently the Paediatric Clinical Development Lead (CDL) at ViiV Healthcare (VH)/GSK, where he is focuses on facilitating access to cabotegravir and dolutegravir for paediatric patients with HIV. He joined VH/GSK in 2023 as Medical Director, contributing to early-stage drug development initiatives, including broadly neutralising antibodies and capsid inhibitors, before advancing to his current role. Prior to joining VH/GSK, he was a PhD candidate at the University of Cape Town, earning his doctorate in Clinical Pharmacology. His research concentrated on the adverse effect profile of dolutegravir in an African population, specifically examining pharmacogenetic predictors, as well as the presence of a concentration-response relationship for weight gain and neuropsychiatric adverse effects. Additionally, he was Lead Investigator on a Wellcome trust funded randomised controlled trial that evaluated clinical outcomes with dolutegravir single dosing in adults with HIV receiving rifampicin-based anti-tuberculosis therapy, and Co-Investigator on a randomised controlled clinical trial assessing dolutegravir-based antiretroviral treatment as second-line therapy in adults with HIV failing a first-line regimen. He holds an MBChB from the University of Pretoria and has specialised in Clinical Pharmacology, obtaining an MMed and FCCP from the University of Cape Town and the South African Colleges of Medicine, respectively.

Salvatore D’Agate is a research fellow in the Clinical Pharmacology and Therapeutics group at University College London (UCL) and at the Italian National Research Council (CNR). His current research focuses on the model-based characterisation of the impact of ontogeny, maturation and disease-related factors on drug disposition and dosing regimens. In particular, he is interested in the optimisation of dosing regimens for antibiotics and antivirals in neonates and young children. Concurrently, he works with ERA4TB, a European consortium aimed at accelerating the development of new treatment regimens for tuberculosis. His main task is to develop drug-disease models describing bacterial growth dynamics in vitro and in vivo to aid the quantification of the efficacy of antibiotics both as monotherapy and in combination taking into account the role of immune system. Previously, he worked as a consultant for GSK in a project aimed at characterising disease progression and risk of acute urinary retention in patients with benign prostate hyperplasia, and at assessing the impact of drugs with disease-modifying and symptomatic treatment effects on the progression of LUTS symptoms and on the risk of acute urinary retention.

Ronaldo Morales Junior is a Clinical Pharmacist specializing in pediatric care and precision dosing. He holds a Ph.D. in Pharmaceutical Sciences from the University of São Paulo (Brazil) and currently works as a Postdoctoral Researcher in Clinical Pharmacology at Cincinnati Children's. His research focuses on the pharmacokinetics and pharmacodynamics of antimicrobial agents, with a particular emphasis on critically ill children, post-transplant patients, and neonates. He investigates key factors affecting drug disposition to optimize antibiotic dosing strategies.

Dr Julia Netylko completed her medical degree at Moscow State University, followed by residency in cardiology. She joined the Cancer Therapies group at the Murdoch Children’s Research Institute in October 2024. Her research focuses on pharmacogenomics in paediatric oncology, with current projects investigating genetic predisposition to anthracycline-induced cardiotoxicity and genotype-informed dosing of tacrolimus in solid organ transplant recipients. Julia is passionate about advancing personalised medicine approaches to improve treatment safety and outcomes for children.